Kevin Love

3.3K posts

Kevin Love

Kevin Love

@kevinlove

https://t.co/RUkPL2wnQU

Katılım Kasım 2010
623 Takip Edilen2.7M Takipçiler
Kevin Love retweetledi
Christian Angermayer
Christian Angermayer@C_Angermayer·
Today’s Presidential Executive Order on #psychedelics marks a major milestone in the history of these valuable substances. It corrects a fundamental mistake made in 1970, when President Nixon established the Controlled Substances Act (CSA) and classified psychedelics as Schedule I substances - a designation that had no basis. For largely political reasons, these highly promising compounds were pushed out of the medical realm and into illegality. Now, they are coming back - with force. The executive order is directing the Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA), the Department of Justice and other federal agencies to reduce the red tape and restrictions that have long stymied researchers and biotech companies in the field. As a result, I expect drug approval processes to accelerate and become less costly. I am very proud that @ataibeckley is at the forefront of this field, with one of the broadest pipelines in psychedelics, including clinical programs focused on DMT, 5-MeO-DMT, R-MDMA and – as previously disclosed - ibogaine and additional novel, discovery compounds in various stages of preclinical development. Since I founded AtaiBeckley in 2017, and seed-funded @COMPASSPathway that same year, these two companies have raised more than $1.5 billion to advance clinical research and development of psychedelic therapies. As access to capital was limited early on - since most investors dismissed the idea as crazy - I invested over $100 million of my own capital and have never sold a single $ATAI share (nor do I intend to). The public sentiment around psychedelics as FDA-regulated drugs has gone from “this is a crazy idea that will ruin your career” to being on the verge of what the market anticipates will be the first regulatory approval of a psychedelic with COMP360… all in less than a decade. What a journey. But we are still only at the beginning. I strongly believe the world will benefit from the full spectrum of psychedelic compounds that demonstrate medical and commercial value. I also believe that delivery mechanisms and treatment duration are critical, as these therapies must fit within the commercial realities and infrastructure of the U.S. and global healthcare systems. That conviction is exactly why AtaiBeckley has built such a broad and diversified pipeline with a focus on short-acting psychedelics: x.com/C_Angermayer/s… Once approved, I expect physicians will determine which treatments are best suited to specific patient profiles. Over time, better data and real-world evidence will significantly improve this matching - delivering the right FDA-approved treatment to the right patient. This level of presidential attention also reinforces another long-held belief of mine: the support – and potential use - for psychedelic therapies is far larger and broader than most people have historically assumed. Take once more AtaiBeckley as an example. Most analysts currently model compounds like BPL-003 and VLS-01 primarily within treatment-resistant depression (TRD) - patients who have already failed at least two antidepressant treatments. But my own personal view (and ultimate vision) would be to progress to these treatments sooner, especially when existing treatments often have limited efficacy and significant side effects. Given the favorable safety profiles and promising efficacy of psychedelics we are seeing in the clinical trials run to date, and based on my own extensive discussions with therapists who have worked with these compounds, I personally believe psychedelic therapies have the potential to become first-line treatments - and, over time, even potentially play a role in prevention. Thank you, @realDonaldTrump, for today’s important signal of support, and @joerogan for driving it! Most importantly, thank you to everyone working behind the scenes to make this possible today - and to the fellow drug developers advancing these therapies. This has been, and will continue to be, a truly collaborative effort. You can all be proud of the meaningful difference you are about to make for the millions of patients in need.
Christian Angermayer tweet media
English
61
113
660
375.9K
Kevin Love retweetledi
NBA
NBA@NBA·
ACE BAILEY is the 5th-youngest player in NBA history with 3-straight 25+ point games! The only players younger: LeBron James Cooper Flagg Carmelo Anthony Devin Booker
English
125
961
11.1K
695.8K
Kevin Love
Kevin Love@kevinlove·
Every kid deserves to feel like the GOAT. Proud to partner with @SonyAnimation on free activities that help students believe in themselves, build resilience, and manage emotions. Let's give them the tools to thrive. Watch the full Roarball interview here: youtu.be/lLevEOVOWqg
YouTube video
YouTube
English
173
105
588
656.7K
Kevin Love
Kevin Love@kevinlove·
Most of you know my love for the mental health space. I’m working on something new and would appreciate you sending questions related to mental health - and with the help of experts - we will get those answered in video format. 🙏🏻🙏🏻🙏🏻
English
38
34
577
78.9K
Kevin Love
Kevin Love@kevinlove·
Never thought I’d be a math problem. Welcome to the NBA.
English
1.5K
2.9K
75.8K
6.6M
Kevin Love retweetledi
Christian Angermayer
Christian Angermayer@C_Angermayer·
Today, $ATAI announced outstanding Phase 2b data for BPL-003 (5-MeO-DMT). In parallel, core shareholders – including myself and pharma company @ferring – demonstrated conviction by investing $50 million together with top-tier biotech funds. I firmly believe psychedelics have the potential to heal millions and fundamentally transform mental health treatment. In doing so, they will make a deep, positive dent in the universe. Especially in the times ahead, we humans need psychedelics more than ever. My hope is for @atai_life to lead this revolution – scientifically, commercially, and spiritually. atai is the greatest entrepreneurial endeavour of my life, and I believe it will yield rich returns – both financial and emotional – for everyone involved. Check out my latest blog post: christianangermayer.substack.com/p/atai-life-sc…
Christian Angermayer tweet media
English
79
53
261
312.9K
Kevin Love retweetledi
Letterboxd
Letterboxd@letterboxd·
Four Favorites with Kevin Love of the @MiamiHEAT 🏀 Watch the full interview on our Youtube: boxd.it/aL2
English
14
48
1K
436.8K
Kevin Love retweetledi
OffBall
OffBall@OffBall_News·
Old teammates. New takes. Real-time reactions. Kevin Love, Channing Frye, and Kyle Lowry are reuniting for ‘The Chat’ during Game 4 of the NBA Finals 🏀 Snag one of the limited spots now... we go live on WhatsApp Friday at tipoff » offball.ws/403kvk5
OffBall tweet media
English
36
43
389
484.6K
Kevin Love
Kevin Love@kevinlove·
Very excited for this @C_Angermayer — Congratulations!!!
Christian Angermayer@C_Angermayer

Today marks a major milestone in my psychedelic journey. @atai_life (Nasdaq: $ATAI), the psychedelic medicine company I founded in 2018, has announced the merger with @BeckleyPsytech — positioning atai, soon to be renamed atai Beckley, as the undisputed leader in the field of psychedelics. Just as exciting: traditional pharma is finally entering the psychedelic space. Ferring Ventures, part of @ferring, has built a 7.5% stake in atai — accumulating shares on the open market over the last months and now investing an additional $20 million alongside the acquisition. I’m incredibly proud of this powerful vote of confidence. I’ve written a longer blog post about the potential of psychedelics, atai, and why this merger is such a game-changer. Check it out here: christianangermayer.substack.com/p/atai-acquire…

English
6
0
28
61.2K
Kevin Love retweetledi
Miami HEAT
Miami HEAT@MiamiHEAT·
As #MentalHealthAwarenessMonth comes to an end, we feature @kevinlove's time at Miami Jackson Senior High School leading writing prompts, affirmations and mindfulness activities to help students achieve a more positive headspace.
English
6
42
276
47.6K